Genetic markers indicate which non-small-cell lung cancer patients may benefit from adjuvant therapy

Wednesday, December 15, 2010 (Last Updated: 12/16/2010)

WEDNESDAY, Dec. 15 (HealthDay News) -- Using a tool based on six gene markers, oncologists may be better able to identify stage I non-small-cell lung cancer (NSCLC) patients more at risk for relapse who might benefit from adjuvant therapy, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, held from Dec. 9 to 11.

Jimmy Ruiz, M.D., of the Wake Forest University School of Medicine in Winston-Salem, N.C., and colleagues analyzed the microarray expression profiles of stage I NSCLC tumors from more than 300 stage IA/IB patients to construct and validate a tool for determining prognosis based on genetic information.

From a training cohort of 120 subjects, the team identified a six-gene prognostic classifier that could stratify patients into three groups -- high-, intermediate-, and low-risk -- with significantly different relapse rates. They validated the six-gene stage I NSCLC classifier ("S1N" classifier) in a cohort of 179 subjects and found the results for high-risk subjects to be similar to those in the test group, estimating a more than 80 percent relapse rate within five years. However, the low- and intermediate-risk groups' survival times did not remain significantly different.

"The six-gene S1N classifier identifies a high-risk group of stage I patients for whom surgery alone is insufficient. High-risk patients identified by the S1N classifier may benefit from the chemotherapy offered to later stage patients," the authors write.

More Information

Specialties Hematology & Oncology

Copyright © 2010 HealthDay. All rights reserved.


Nutrition and Diet for Prostate Cancer [Webinar]
by OncoLink Editorial Team
September 06, 2013

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015